|
Synonyms: Brevibloc® | SL-8052
esmolol is an approved drug (FDA (1986))
Compound class:
Synthetic organic
Comment: Esmolol is a β-blocker.
Marketed formulations may contain esmolol hydrochloride (PubChem CID 104769). Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Baker JG, Fromont C, Bruder M, Thompson KSJ, Kellam B, Hill SJ, Gardiner SM, Fischer PM. (2020)
Using Esterase Selectivity to Determine the In Vivo Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β-Blockers. ACS Pharmacol Transl Sci, 3 (4): 737-748. [PMID:32832874] |
|
2. Lim VJY, Proudman RGW, Monteleone S, Kolb P, Baker JG. (2023)
The Isoleucine at Position 118 in Transmembrane 2 Is Responsible for the Selectivity of Xamoterol, Nebivolol, and ICI89406 for the Human β1-Adrenoceptor. Mol Pharmacol, 103 (2): 89-99. [PMID:36351797] |
|
3. Nasrollahi-Shirazi S, Sucic S, Yang Q, Freissmuth M, Nanoff C. (2016)
Comparison of the β-Adrenergic Receptor Antagonists Landiolol and Esmolol: Receptor Selectivity, Partial Agonism, and Pharmacochaperoning Actions. J Pharmacol Exp Ther, 359 (1): 73-81. [PMID:27451411] |